A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics of Sulfatinib in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Sulfatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 23 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 02 Aug 2016 According to a Chi-Med media release, the company expects to initiate a U.S. Phase II (see profile 2629090) in 2017 based on the conclusion of this trial.